- Home
- ENLV vs CGEN Comparison
ENLV vs CGEN Comparison
Compare ENLV & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ENLV | CGEN |
|---|---|---|
| Founded | 2005 | 1993 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.3M | 220.7M |
| IPO Year | 1995 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ENLV | CGEN |
|---|---|---|
| Price | $1.16 | $1.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $13.00 | $4.00 |
| AVG Volume (30 Days) | 466.5K | ★ 569.1K |
| Earning Date | 03-30-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $6,903,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $164.92 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.66 | $1.13 |
| 52 Week High | $2.10 | $2.66 |
Technical Indicators
Market Signals| Indicator | ENLV | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 62.69 | 36.72 |
| Support Level | $1.01 | $2.04 |
| Resistance Level | $1.26 | $2.08 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 66.17 | 0.64 |
Price Performance
Historical ComparisonAbout ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.